NCT00802867View on ClinicalTrials.gov

Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™

PHASE4CompletedINTERVENTIONAL

Enrollment

989

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

June 30, 2005

Study Completion Date

September 30, 2005

Conditions

DiphtheriaTetanusPertussisPolioHaemophilus Infection

Interventions

BIOLOGICAL

Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)

0.5 mL, Intramuscular

Trial Locations (19)

12208

Albany

14620

Rochester

15241

Pittsburgh

27514

Chapel Hill

28779

Sylva

30322

Atlanta

32806

Orlando

37232

Nashville

54449

Marshfield

68131

Omaha

72205

Little Rock

72401

Jonesboro

78205

San Antonio

84041

Layton

90502

Torrance

94612

Oakland

98664

Vancouver

02115

Boston

01801

Woburn

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00802867 - Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ | Biotech Hunter | Biotech Hunter